112 results about "Monosaccharide metabolism" patented technology

The invention belongs to the field of biological medicines, relates to novel uses of artemether and artemisinin analogues in pharmacy, particularly relates to uses of artemether in preparation of preparations promoting steatolysis and improving carbohydrate metabolism, and more particularly relates to uses of artemether and artemisinin analogues in preparation of preparations promoting browning of white adipose and preparations reducing body weight and improving metabolism. In-vivo and in-vitro experiments prove that the artemisinin analogues have a function of inducing browning of white adipose, and through promoting the browning of white adipose, effects of reducing body weight, improving metabolism, maintaining a carbohydrate metabolism steady state, relieving fatty liver and improving diabetes related symptoms are achieved. Clinical application practices show that intolerable adverse effects of the artemisinin analogues have not been found, the artemisinin analogues can be further prepared into preparations promoting steatolysis and improving carbohydrate metabolism and the preparations are used for treating and improving metabolism related diseases.

A method is described for the treatment of obesity or other disorders, by electrical activation or inhibition of the sympathetic nervous system. This activation or inhibition can be accomplished by electrically stimulating the greater splanchnic nerve or other portion of the sympathetic nervous system using an implantable pulse generator. This nerve activation can result in reduced food intake and increased energy expenditure. Reduced food intake may occur through a variety of mechanisms that reduce appetite and cause satiety. Increased adrenal gland hormone levels will result in increased energy expenditure. Fat and carbohydrate metabolism, which are also increased by sympathetic nerve activation, will accompany the increased energy expenditure.

This invention provides a method for diagnosing geriatric diseases associated with insulin resistance, such as type II diabetes, at an early stage and a method for monitoring the therapeutic effects of agents for type II diabetes by quantitatively assaying GBP28 with the use of a monoclonal antibody that can assay adiponectin (GBP28) in a sample.

A solid oral diagnostic test meal is provided that contains a polysaccharide, wherein the oral diagnostic test meal provides a medically controlled quantity of glycemic carbohydrate after being ingested by a vertebrate subject. In addition, methods and kits are provided for using the diagnostic test meal to monitor postprandial glucose to screen insulin levels and / or diagnose disorders of carbohydrate metabolism, to manage subjects being treated with antidiabetic agents, to self-diagnose diabetes and self-manage diet and antidiabetic drug dosage, and to calculate the glycemic index of a test food.

Methods and compositions for modulating carbohydrate metabolism in a host are provided. In the subject methods, diacylglycerol acyltransferase (DGAT) activity (specifically DGAT1 activity) is modulated, e.g., reduced or enhanced, to achieve a desired insulin and / or leptin sensitivity, thereby modulating carbohydrate metabolism, e.g., increasing or decreasing blood glucose levels, glucose uptake into cells and assimilation into glycogen. Also provided are pharmaceutical compositions for practicing the subject methods. The subject methods and compositions find use in a variety of applications, including the treatment of hosts suffering conditions associated with abnormal carbohydrate metabolism, such as obesity or diabetes.

The present invention provides a method and composition for ameliorating or reducing the symptoms and signs and for the treatment of obesity, diabetes, and related conditions in a mammal in need thereof, said method comprising administering effective amounts of a pharmaceutically acceptable composition comprising a mixture of probiotic microorganisms with distinct but complementary pathways of carbohydrate metabolism, for a time sufficient to ameliorate, reduce or treat at least one sign or symptom of obesity, diabetes or cardiovascular disease. Compositions having the desired properties, and methods for their use in pharmaceutical and nutritional formulations, are provided.

The present invention is directed to cosmetic and / or pharmaceutical compositions comprising at least one plant lipid, having as its main application the treatment of keratinous materials, particularly skin, hair, scalp, nails and eyelashes, by modulating the expression of genes responsible for ROS metabolism, lipid metabolism, skin integrity, cell renewal, cell differentiation, strengthening the skin barrier, calcium metabolism, cell proliferation, tissue healing and / or repair, cell adhesion, carbohydrate metabolism, hydration, skin homeostasis / maintenance, skin defense and / or protection, remodeling and / or extracellular matrix synthesis, skin peeling, tissue maintenance, cell signaling, normal development of the epidermis, epidermal barrier function, development of the skin, dermis-epidermis junction, anti-inflammatory or antioxidant action in keratinous materials, through the modulation of the expression of the genes involved in said functions. The present invention also teaches methods of modulating the expression of genes responsible for such functions of keratinous materials and the use of said plant lipids in the preparation of said compositions.

The invention relates to the field of measurements for diagnostic purposes, in particular to measurements associated with assessing the influence of food loads on a human organism. In order to determine the glycaemic index on the basis of the results of measuring glucose concentration in a person's blood, the period of time [delta]t from the beginning of an increase in the concentration of glucosecaused by an intake of food up to reaching a maximum value of the concentration of glucose is determined and the maximum increase in the concentration of glucose in the blood [delta]G max for a specified period of time is determined. Furthermore, the glycaemic index of food is determined as a ratio of the maximum increase in the concentration of glucose in the blood [delta]G max to the maximum increase in the concentration of glucose in the blood which would enter a human organism upon the intake of pure glucose, the amount of which is equal to the amount of carbohydrates contained in the consumed food, and which is determined as a value proportional to the production of [delta]G max per [delta]t. The invention substantially simplifies the procedure of determining the glycaemic index of actual food and makes it possible, on the basis thereof, to produce simple personal devices for monitoring carbohydrate metabolism.